NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Robert Hayes, CEO of Sharps Technology, who will share insight into the Company's recent Asset Purchase Agreement and accompanying five-year, $200 million ...

Signed PO secures first 12 months of syringe product orders against Sharps and Nephron’s five-year, $200 million Syringe Sales Agreement. Current Asset Purchase Agreement closing timeline is on track for expected prefillable syringe product shipments to begin by Q2 of 2025. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, received a signed $30 ...

Signed PO secures first 12 months of syringe product orders against Sharps and Nephron’s five-year, $200 million Syringe Sales Agreement. Current Asset Purchase Agreement closing timeline is on track for expected prefillable syringe product shipments to begin by Q2 of 2025. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in- class syringe products, received a signed $3 ...

InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has progressed with the payment of $1 million into third-party escrow account. Closing on the Asset Purchase and the Syringe Sales Agreement, for product orders totaling over $200 million for the first five years of operation, is expected within the next 60 days. Based on the most likely timeframe, product shipments from the SC facility are planned to begin by Q2 of 2025. NEW YORK, June 05, 2024 (GLOBE NE ...

Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S.  Signed Syringe Sales Agreement will secure product orders totaling over $200 million for the first five years of operation. Sharps is negotiating additional pharma-segment purchase commitments for orders over the next three years, with shipments expected to begin by Q2 of 2025. Demand for Sharps products is increasing due to recent FDA warn ...

Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S.  Through the syringe Sales Agreement and the closing of the APA, Sharps will secure product orders totaling over $200 million for the first five years of operation Sharps is negotiating additional pharma-segment PFS purchase commitments for orders over the next 3 years, with shipments expected to beg ...

Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S. Through the syringe Sales Agreement and the closing of the APA, Sharps will secure product orders totaling over $200 million for the first five years of operation Sharps is negotiating additional pharma-segment PFS purchase commitments for orders over the next 3 years, with shipments expected to begi ...

Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began raising quality concerns over Chinese-manufactured syringes in November 2023, resulting in multiple recalls and warnings for these products during the first quarter of 2024, and has advised that healthcare facilities should use plastic syringes produced elsewhere. The tariff rate on Chinese-made syringes and needles was raised from 0% to 50% by the Biden Administration in May 2024. NEW YORK, May 28, ...

Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began raising quality concerns over Chinese-manufactured syringes in November 2023, resulting in multiple recalls and warnings for these products during the first quarter of 2024, and has advised that healthcare facilities should use plastic syringes produced elsewhere. The tariff rate on Chinese-made syringes and needles was raised from 0% to 50% by the Biden Administration in May 2024. NEW YORK, May 28, ...

Sharps Technology (NASDAQ:STSS) stock is rocketing higher on Tuesday after the company announced a potential five-year purchase agreement with Nephron. This agreement has Nephron making Sharps Technology its exclusive pre-filled copolymer syringe manufacturer. That will see it purchase a minimum of $188.5 million of syringes over those five years. The purchase agreement also includes an amendment to the cash consideration between the two companies. That includes $35 million payable in cash on closing. $1 mi ...